Journal Mobile Options
Table of Contents
Vol. 50, No. 1, 2003
Issue release date: June 2003

Assessment of Neuroinflammation and Microglial Activation in Alzheimer’s Disease with Radiolabelled PK11195 and Single Photon Emission Computed Tomography

A Pilot Study

Versijpt J.J. · Dumont F. · van Laere K.J. · Decoo D. · Santens P. · Audenaert K. · Achten E. · Slegers G. · Dierckx R.A. · Korf J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: Inflammation contributes to degeneration in Alzheimer’s disease (AD), not simply as a secondary phenomenon, but primarily as a significant source of pathology. [123I]iodo-PK11195 is a single photon emission computed tomography (SPECT) ligand for the peripheral benzodiazepine receptor, the latter being expressed on microglia (brain resident macrophages) and upregulated under inflammatory circumstances. The objectives were to assess AD inflammation by detecting [123I]iodo-PK11195 uptake changes and investigate how uptake values relate with perfusion SPECT and neuropsychological findings. Methods: Ten AD and 9 control subjects were included. [123I]iodo-PK11195 SPECT images were realigned into stereotactic space where binding indices, normalized on cerebellar uptake, were calculated. Results: The mean [123I]iodo-PK11195 uptake was increased in AD patients compared with controls in nearly all neocortical regions; however, statistical significance was only reached in the frontal and right mesotemporal regions. Significant correlations were found between regional increased [123I]iodo-PK11195 uptake and cognitive deficits. Conclusions: [123I]iodo-PK11195 is a cellular disease activity marker and allows in vivo assessment of microglial inflammation in AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Geldmacher DS, Whitehouse PJ: Evaluation of dementia. N Engl J Med 1996;335:330–336.
  2. Kuhlmann AC, Guilarte TR: Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem 2000;74:1694–1704.
  3. Neve RL, Robakis NK: Alzheimer’s disease: A re-examination of the amyloid hypothesis. Trends Neurosci 1998;21:15–19.
  4. Mesulam MM: Neuroplasticity failure in Alzheimer’s disease: Bridging the gap between plaques and tangles. Neuron 1999;24:521–529.
  5. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, MacKenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer’s disease. Neurobiol Aging 2000;21:383–421.
  6. Gonzalez-Scarano F, Baltuch G: Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999;22:219–240.
  7. McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, McIlroy SP, Passmore AP: Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer’s disease and vascular dementia: A case-control study. Lancet 2001;357:436–439.
  8. McGeer PL, McGeer EG: Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001;58:1790–1792.
  9. McGeer PL, Schulzer M, McGeer EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurology 1996;47:425–432.
  10. Stewart WF, Kawas C, Corrada M, Metter EJ: Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997;48:626–632.
  11. in ‘t Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001;345:1515–1521.
  12. Zandi PP, Breitner JCS: Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001;22:811–817.

    External Resources

  13. De Strooper B, Konig G: An inflammatory drug prospect. Nature 2001;414:159–160.
  14. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Wilson P, Kogan F: Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993;43:1609–1611.
  15. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999;53:197–201.
  16. van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ: Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 2001;358:455–460.
  17. Aisen PS, Schmeidler J, Pasinetti GM: Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology 2002;58:1050–1054.
  18. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000;408:982–985.
  19. Richards JG, Mohler H: Benzodiazepine receptors. Neuropharmacology 1984;23:233–242.
  20. Ruff MR, Pert CB, Weber RJ, Wahl LM, Wahl SM, Paul SM: Benzodiazepine receptor-mediated chemotaxis of human monocytes. Science 1985;229:1281–1283.
  21. Diorio D, Welner SA, Butterworth RF, Meaney MJ, Suranyi CB: Peripheral benzodiazepine binding sites in Alzheimer’s disease frontal and temporal cortex. Neurobiol Aging 1991;12:255–258.
  22. Banati RB, Myers R, Kreutzberg GW: PK (‘peripheral benzodiazepine’)-binding sites in the CNS indicate early and discrete brain lesions: Microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 1997;26:77–82.
  23. Ramsay SC, Weiller C, Myers R, Cremer JE, Luthra SK, Lammertsma AA, Frackowiak RS: Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet 1992;339:1054–1055.
  24. Banati RB, Goerres GW, Myers RN, Gunn RN, Turkheimer FE, Kreutzberg GW, Brooks DJ, Jones T, Duncan JS: [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis. Neurology 1999;53:2199–2203.
  25. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R: The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123:2321–2337.
  26. Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW, Jones T, Banati RB: In vivo visualization of activated glia by [11C](R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001;124:2014–2027.
  27. Goerres GW, Revesz T, Duncan J, Banati RB: Imaging cerebral vasculitis in refractory epilepsy using [11C](R)-PK11195 positron emission tomography. AJR Am J Roentgenol 2001;176:1016–1018.
  28. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB: In vivo measurement of activated microglia in dementia. Lancet 2001;358:461–467.
  29. Dumont F, De Vos F, Versijpt J, Jansen HM, Korf J, Dierckx RA, Slegers G: In vivo evaluation in mice and metabolism in blood of human volunteers of [123I]iodo-PK11195: A possible single-photon emission tomography tracer for visualization of inflammation. Eur J Nucl Med 1999;26:194–200.
  30. Versijpt J, Dumont F, Thierens H, Jansen H, De Vos F, Slegers G, Santens P, Dierckx RA, Korf J: Biodistribution and dosimetry of [123I]iodo-PK 11195: A potential agent for SPET imaging of the peripheral benzodiazepine receptor. Eur J Nucl Med 2000;27:1326–1333.
  31. Jagust W, Thisted R, Devous MD Sr, Van Heertum R, Mayberg H, Jobst K, Smith AD, Borys N: SPECT perfusion imaging in the diagnosis of Alzheimer’s disease: A clinical-pathologic study. Neurology 2001;56:950–956.
  32. Morgan CD, Baade LE: Neuropsychological testing and assessment scales for dementia of the Alzheimer’s type. Psychiatr Clin North Am 1997;20:25–43.
  33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  34. Van Laere K, Versijpt J, Audenaert K, Koole M, Goethals I, Achten E, Dierckx R: 99mTc-ECD brain perfusion SPET: Variability, asymmetry and effects of age and gender in healthy adults. Eur J Nucl Med 2001;28:873–887.
  35. Gildersleeve DL, Lin TY, Wieland DM, Ciliax BJ, Olson JM, Young AB: Synthesis of a high specific activity 125I-labeled analog of PK 11195, potential agent for SPECT imaging of the peripheral benzodiazepine binding site. Int J Rad Appl Instrum B 1989;16:423–429.
  36. Van Laere K, Koole M, D’Asseler Y, Versijpt J, Audenaert K, Dumont F, Dierckx R: Automated stereotactic standardization of brain SPECT receptor data using single-photon transmission images. J Nucl Med 2001;42:361–375.
  37. Sette G, Baron JC, Young AR, Miyazawa H, Tillet I, Barre L, Travere JM, Derlon JM, MacKenzie ET: In vivo mapping of brain benzodiazepine receptor changes by positron emission tomography after focal ischemia in the anesthetized baboon. Stroke 1993;24:2046–2057.
  38. Van Laere K, Koole M, Kauppinen T, Monsieurs M, Bouwens L, Dierckx R: Nonuniform transmission in brain SPECT using 201Tl, 153Gd, and 99mTc static line sources: Anthropomorphic dosimetry studies and influence on brain quantification. J Nucl Med 2000;41:2051–2062.
  39. de Jonghe JF, Krijgsveld S, Staverman K, Lindeboom J, Kat MG: Differentiation between dementia and functional psychiatric disorders in a geriatric ward of a general psychiatric hospital using the ‘Amsterdam Dementia-Screening Test’. Ned Tijdschr Geneeskd 1994;138:1668–1673.
  40. Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE: PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer’s disease. J Nucl Med 1995;36:2207–2210.
  41. De Vos F, Dumont F, Slegers G, Dierckx RA: Pharmacological comparison between 11C-2′-iodo-PK11195 and 123I-2′-iodo-PK11195. J Nucl Med 2001;42:252P.
  42. Calingasan NY, Erdely HA, Anthony AC: Identification of CD40 ligand in Alzheimer’s disease and in animal models of Alzheimer’s disease and brain injury. Neurobiol Aging 2002;23:31–39.

    External Resources

  43. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology: Assessment of brain SPECT. Neurology 1996;46:278–285.
  44. Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL, Vinters HV: Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Arch Neurol 1999;56:1254–1261.
  45. Cummings JL: Cognitive and behavioral heterogeneity in Alzheimer’s disease: Seeking the neurobiological basis. Neurobiol Aging 2000;21:845–861.

    External Resources

  46. Perl DP, Olanow CW, Calne D: Alzheimer’s disease and Parkinson’s disease: Distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 1998;44:S19-S31
  47. Waldemar G: Functional brain imaging with SPECT in normal aging and dementia. Methodological, pathophysiological, and diagnostic aspects. Cerebrovasc Brain Metab Rev 1995;7:89–130.
  48. Mann UM, Mohr E, Gearing M, Chase TN: Heterogeneity in Alzheimer’s disease: Progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. J Neurol Neurosurg Psychiatry 1992;55:956–959.
  49. Cagnin A, Myers R, Gunn RN, et al: Imaging activated microglia in the ageing human brain. J Cereb Blood Flow Metab 1999;19:S820.
  50. Juottonen K, Laakso MP, Partanen K, Soininen H: Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. Am J Neuroradiol 1999;20:139–144.
  51. Syed GM, Eagger S, Toone BK, Levy R, Barrett JJ: Quantification of regional cerebral blood flow (rCBF) using 99mTc-HMPAO and SPECT: Choice of the reference region. Nucl Med Commun 1992;13:811–816.
  52. Joachim CL, Morris JH, Selkoe DJ: Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 1989;135:309–319.
  53. Rozemuller JM, Stam FC, Eikelenboom P: Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer’s disease. Neurosci Lett 1990;119:75–78.
  54. Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ: Choice of reference region in the quantification of single-photon emission tomography in primary degenerative dementia. Eur J Nucl Med 1994;21:503–508.
  55. Pickut BA, Dierckx RA, Dobbeleir A, Audenaert K, Van Laere K, Vervaet A, De Deyn PP: Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type. Psychiatry Res 1999;90:103–112.
  56. Torres SR, Frode TS, Nardi GM, Vita N, Reeb R, Ferrara P, Ribeiro-Do-Valle RM, Farges RC: Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation. Eur J Pharmacol 2000;408:199–211.
  57. Klegeris A, McGeer EG, McGeer PL: Inhibitory action of 1-(2-chlorophenyl)-N-methyl-N- (1-methylpropyl)-3-isoquinolinecarboxamide (PK 11195) on some mononuclear phagocyte functions. Biochem Pharmacol 2000;59:1305–1314.

    External Resources

  58. Waterfield JD, McGeer EG, McGeer PL: The peripheral benzodiazepine receptor ligand PK 11195 inhibits arthritis in the MRL-lpr mouse model. Rheumatology (Oxford) 1999;38:1068–1073.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50